TCL Archive FDA Approves Gemzar For Ovarian Cancer, Contradicting ODAC Recommendation; Continues Agency Trend to Recognize Progression-Free Survival As An Endpoint. July 21, 2006
TCL Archive ODAC Votes to Nix Amgen’s Drug Xgeva For Proposed Prostate Cancer Indication February 17, 2012